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Summary 28 
Many viruses have evolved strategies to deregulate the host immune system. These 29 
strategies include mechanisms to subvert or recruit the host cytokine network. Interleukin-10 30 
(IL-10) is a pleiotropic cytokine that has both immunostimulatory and immunosuppressive 31 
properties. However, its key features relate mainly to its capacity to exert potent 32 
immunosuppressive effects. Several viruses have been shown to up regulate the expression of 33 
cellular IL-10 (cIL-10), with, in some cases, enhancement of infection by suppression of immune 34 
functions. Other viruses encode functional orthologues of cIL-10, called viral IL-10s (vIL-10s). 35 
The present review is devoted to these virokines. To date, vIL-10 orthologues have been reported 36 
for 12 members of the family Herpesviridae, two members of the family Alloherpesviridae, and 37 
seven members of the family Poxviridae. Study of vIL-10s demonstrated several interesting 38 
aspects on the origin and the evolution of these viral genes; such as for example, the existence of 39 
multiple (potentially up to 9) independent gene acquisition events at different times during 40 
evolution, viral gene acquisition resulting from recombination with cellular genomic DNA or 41 
cDNA derived from cellular mRNA, and the evolution of cellular sequence in the viral genome 42 
to restrict the biological activities of the viral orthologues to those beneficial for the virus life 43 
cycle. In this review, various aspects of the vIL-10s described to date are reviewed, including 44 
their genetic organization, protein structure, origin, evolution, biological properties and potential 45 
in applied research. 46 
47 
1. Introduction 48 
For millions of years, viruses have been co-evolving with their hosts. During this process, 49 
they have had to deal with the most complex aspects of host physiology, often mimicking, 50 
hijacking or sabotaging host biological processes to their benefit. In this respect, many viruses 51 
have evolved strategies to deregulate the host immune response in order to avoid immune 52 
surveillance and elimination from the host. These strategies include mechanisms to deregulate 53 
the host cytokine network. 54 
The Interleukin (IL)-10 family of cytokines and the related Interferon (IFN) family of 55 
cytokines form the larger class II cytokine family (Ouyang et al., 2011). The IL-10 family of 56 
cytokines can be categorized into three subgroups, based primarily on biological functions: (i) 57 
IL-10 itself; (ii) the IL-20 subfamily cytokines composed of IL-19, IL-20, IL-22, IL-24 and 58 
IL-26; and (iii) the type III IFN group (also called IFN λs) (Ouyang et al., 2011; Pestka et al., 59 
2004). 60 
IL-10 is a pleiotropic cytokine, with both immunostimulatory and immunosuppressive 61 
properties (Moore et al., 2001). However, its key features relate mainly to its capacity to exert 62 
potent effects in the latter category via several mechanisms. Various viruses have been shown to 63 
up-regulate the expression of cellular IL-10 (cIL-10), with, in some cases, an enhancement of 64 
infection by suppression of immune functions (Brady et al., 2003; Brockman et al., 2009; Díaz-65 
San Segundo et al., 2009; Yu et al., 2008). These studies suggest that cIL-10 expression during 66 
the course of infection might be beneficial for the pathogens concerned. 67 
Further supporting this conclusion, several viruses encode orthologues of cIL-10, called 68 
viral IL-10s (vIL-10s), that appear to have been acquired by viruses on multiple independent 69 
occasions from their host during evolution. This review is devoted to these virokines. Various 70 
aspects of vIL-10 are described, including their genetic organization, protein structure, origin, 71 
evolution, biological properties in vitro and in vivo, and potential in applied research. 72 
 73 
2. Discovery of vIL-10s 74 
Cloning and sequencing of the human and mouse IL-10s lead to the identification of the 75 
first vIL-10 orthologue. It was discovered that the uncharacterized open reading frame (ORF) 76 
BCRF1 of Epstein-Barr virus (EBV; human herpesvirus 4) encodes a protein that exhibited high 77 
sequence identity (92.3%) with human IL-10 (Moore et al., 1990). Subsequently, various studies 78 
documented that BCRF1 possesses some of the specific biological activities of cIL-10, and it 79 
was therefore concluded that this ORF encodes a functional viral orthologue of human IL-10 80 
(Hsu et al., 1990; Niiro et al., 1992). Ever since, the sequencing of an increasing number of viral 81 
genomes has revealed a growing list of vIL-10s. To date, vIL-10 orthologues have been reported 82 
for 12 members of the family Herpesviridae, two members of the family Alloherpesviridae, and 83 
seven members of the family Poxviridae (Table 1). 84 
 85 
3. Genetic structure of IL-10 orthologues 86 
The basic structure of the human IL-10 gene consists of five protein-coding exons (I-V) 87 
encoding a spliced mRNA of 1629 bp (including untranslated regions) (Fig. 1) (Moore et al., 88 
2001; Sabat, 2010). The first part of exon I and the last part of exon V encode the 5’- and 3’-89 
untranslated regions, respectively. The remaining parts of exons I and V, together with exons II 90 
to IV, encode a single protein of 178 amino acid residues. The sizes of the exons are largely 91 
conserved among animal species. In contrast, the sizes of the introns show greater variation, and 92 
may be up to 1 kbp in length. 93 
The general intron-exon structure of cIL-10 is only found in ovine herpesvirus 2 94 
(OvHV-2) although the introns are considerably shorter than those of its natural host, the sheep 95 
(Jayawardane et al., 2008). For the other vIL-10s, variations are observed in the number and 96 
positions of introns (Table 1 and Fig. 1) and a large proportion of vIL-10s are intronless. 97 
Viral capture of host genes can result either from recombination between the viral 98 
genome and the host genome during viral replication in the nucleus (provided that the viral 99 
genome enters the nucleus during replication, as it is the case for herpesviruses but not 100 
poxviruses), or from recombination between the viral genome and a retrotranscript (cDNA) of 101 
mRNA (Odom et al., 2009; Shackelton & Holmes, 2004). The latter process requires reverse 102 
transcriptase activity, most likely derived from retrovirus co-infection of the host cell 103 
(Brunovskis & Kung, 1995; Isfort et al., 1992). Direct gene capture from the host genome results 104 
in preservation of the original cellular intron-exon structure, as in OvHV-2 (Jayawardane et al., 105 
2008). Subsequent selective pressure could result in successive shortening or even loss of one or 106 
more introns, as exemplified by the vIL-10 variants not containing the full subset of exons. The 107 
intronless vIL-10 genes most likely represent gene capture via reverse transcription of cellular 108 
mRNA, but could theoretically also represent a final stage of intron loss from a gene originally 109 
captured from genomic DNA. The fact that all poxvirus vIL-10 genes are intronless probably 110 
reflects the cytoplasmic replication cycle of poxviruses, which may exclude the possibility of 111 
direct capture of host genes via recombination in the nucleus (Bratke & McLysaght, 2008). 112 
 113 
4. Origin and evolution of vIL-10s 114 
Bioinformatical analyses were performed in the context of the present review, firstly to 115 
identify all viral sequences encoding IL-10 orthologues that are available in the public databases, 116 
secondly to determine whether these sequences are true vIL-10s or orthologues of cellular genes 117 
related to cIL-10. Methods and sequences used for these analyses are provided as supplementary 118 
material (S1). The viral sequences listed in Table 1 and the 134R gene encoded by Yaba-like 119 
disease virus were detected as viral sequences related to cIL-10 (Lee et al., 2001). Among the 120 
sequences listed in Table 1, a sequence highly homologous to EBV vIL-10 was found in the 121 
bonobo genome sequence. We assumed that this resulted from the sequencing of a contaminating 122 
herpesvirus, hereafter called bonobo herpesvirus (bonobo-HV) (The rational that lead to this 123 
conclusion is described in the supplementary material S2). Fig. 2 presents the phylogenetic 124 
analysis of all the viral sequences detected above, together with cIL-10 orthologues and 125 
representative members of the wider IL-10 family of cytokines. Fig. 2 demonstrates that the 126 
134R protein from Yaba-like disease virus is most closely related to IL-24 proteins, although its 127 
exact position in the phylogenetic tree is not well defined in terms of bootstrap values. Further 128 
supporting the conclusion that the 134R protein is not an IL-10 orthologue, Barlett et al. (2004) 129 
demonstrated that it signalled via the IL-20 receptor complex. Thus, it is clear that the 134R 130 
protein is not a true vIL-10, and it was therefore removed from further analyses. 131 
 Many of the vIL-10 genes are situated in orthologous locations in viral genomes, referred 132 
to here as positional orthology. Given that it is unlikely that gene capture would integrate cIL-10 133 
into the same viral genome location on more than one occasion, positional orthology is assumed 134 
to represent ancient viral capture events in ancestral viruses. Four positionally orthologous sets 135 
of vIL-10 can be defined in the following viral genera: Cytomegalovirus, Lymphocryptovirus, 136 
Parapoxvirus and Capripoxvirus. All four of these sets cluster together in the Bayesian tree 137 
vIL-10s and the cIL-10s of a selection of their hosts (Fig. 3). Based on Fig. 3, it can be 138 
concluded that the positionally orthologous clade of vIL-10s of the genus Lymphocryptovirus 139 
(EBV/ baboon lymphocryptovirus [BaLCV]/ rhesus lymphocryptovirus [RhLCV]/ bonobo-HV) 140 
is nearest neighbour to a clade comprising the corresponding ape cIL-10s. This capture of cIL-10 141 
by an ancestral lymphocryptovirus must therefore have taken place after the divergence of Old 142 
World primates from New World primates 42 million years ago, since marmoset IL-10 is an 143 
outlier to both members of the genus Lymphocryptovirus and Old World primate lineages. The 144 
minimum date for this gene capture is more difficult to estimate, as the resolution of the tree does 145 
not make it possible to distinguish between it having occurred prior to the human-gorilla 146 
divergence, at 9 million years ago, or the ape-monkey divergence, at 29 million years ago. In the 147 
vIL-10s of members of the genus Cytomegalovirus (HCMV and others in that clade), an ancient 148 
capture event can again be inferred because of positional orthology. This event would have to 149 
have taken place before 42 million years ago, which is when the Old and New World monkey 150 
lineages diverged. Apart from HCMV cmvIL-10, the vIL-10s in the genus Cytomegalovirus 151 
clade have the same branching pattern as IL-10s of the hosts. The best explanation for the 152 
anomalous position of HCMV cmvIL-10 in this clade is that there has been particular selective 153 
pressure on HCMV. In this context, it is notable that the nearest relative of HCMV, chimpanzee 154 
cytomegalovirus (CCMV), lacks a vIL-10 gene, suggesting that some evolutionary pressure in 155 
the common ancestor of humans and chimpanzees resulted in the loss of this gene from CCMV 156 
and also its extensive modification in HCMV. Concerning CCMV, as there is only one reported 157 
sequence, even if unlikely, one cannot exclude the possibility that this gene has been lost during 158 
viral replication in cell culture. For the positionally orthologous vIL-10s of members of the 159 
genus Parapoxvirus (orf virus [ORFV]/ bovine papular stomatitis virus [BPSV]/ pseudocowpox 160 
virus [PCPV]), it is apparent that the ancestor of these proteins was captured prior to divergence 161 
of the sheep and goat lineages at 7.3 million years ago. However, it is more difficult to specify a 162 
maximum date for this gene capture event, since the relationships of parapoxvirus vIL-10s to 163 
bovine and cervine IL-10 are poorly resolved. 164 
 The Bayesian tree does not help with the assessment of the vIL-10s of the fish viruses 165 
anguillid herpesvirus 1 (AngHV-1) and cyprinid herpesvirus 3 (CyHV-3), nor of OvHV-2, 166 
canarypox virus (CNPV) or the capripoxviruses (lumpy skin disease virus [LSDV]/ sheeppox 167 
virus [SPV]/ goatpox virus [GPV]). However, it seems unlikely that any of these vIL-10s 168 
represents a recent capture from the host. The capripoxvirus vIL-10s constitute a clade, but its 169 
point of divergence from the host sequences cannot be pinpointed in the same way as for the 170 
parapoxviruses. The only obvious example of a recent gene capture event for the origin of a 171 
vIL-10 is in equid herpesvirus 2 (EHV-2). 172 
Overall, based on positional orthology, amino acid sequence comparisons and the 173 
presumed modes of gene capture, at least eight, and possibly nine (assuming that AngHV-1 and 174 
CyHV-3 vIL-10s represent independent acquisitions), different viral cIL-10 capture events can 175 
be discriminated. 176 
 177 
5. Protein structure of IL-10 orthologues 178 
Amino acid sequence conservation is rather low among the three subgroups of the IL-10 179 
family of cytokines (IL-10, IL-20 subfamily cytokines and type III IFN group) (Zdanov, 2004). 180 
In particular, type III IFNs are closer to type I IFNs than to the IL-10. For example, the amino 181 
acid sequence of IFN-λ3 (which belongs to the type III IFN group) is more similar to that of type 182 
I IFNs (exhibits 33% of similarity) than to the IL-10 (exhibits 23% of similarity) (Gad et al., 183 
2009). Moreover, induction of gene expression and biological activities of type III IFNs are more 184 
similar to those described for type I IFNs (Ouyang et al., 2011). However, IFN-λ3 is structurally 185 
more closely related to the IL-10 family of cytokines, especially IL-22 (Gad et al., 2009) and has 186 
been shown to signal through the same IL-10R2 chain (Ouyang et al., 2011). 187 
Cellular IL-10s are well conserved among species (Lockridge et al., 2000; Moore et al., 188 
2001). Indeed, the high level of conservation among cIL-10s contrasts with the variable (25-189 
97.2%), and frequently low levels of identity observed between vIL-10s and their respective host 190 
IL-10s (Table 1). However, as illustrated in Fig. 1 (colour code) the percentage of conservation is 191 
not distributed uniformly along vIL-10s. It is generally higher for amino acid regions 192 
corresponding to the regions encoded by cIL-10 exons 1 (with exception of the signal peptide 193 
region), 3 and 5. 194 
Independent of the level of identity between vIL-10s and cIL-10s, the former share many 195 
features with the latter. Firstly, cIL-10s and vIL-10s are secreted proteins. They are synthesized 196 
as precursors expressing a 17-33 residue hydrophobic signal peptide at the N terminus (Table 1). 197 
This peptide is cleaved during secretion (Kotenko & Pestka, 2001). Secondly, all cIL-10s encode 198 
two family signature motifs: L-[FILMV]-X3-[ILV]-X3-[FILMV]-X5-C-X5-[ILMV]-[ILMV]-199 
X(3)-L-X2-[IV]-[FILMV] and KA-X2-E-X-D-[ILV]-[FLY]-[FILMV]-X2-[ILMV]-[EKQZ] 200 
(Pinto et al., 2007; Zhang et al., 2005). These motifs, which are essential for the structure and the 201 
function of cIL-10s, are conserved to a large extent in vIL-10s. Thirdly, despite the variable 202 
sequence homology observed between cIL-10s and vIL-10s at the amino acid sequence level, 203 
their determined or predicted structures are highly conserved (Fig. 4). The crystal structure of 204 
human IL-10 has been determined as free ligand (Walter & Nagabhushan, 1995; Yoon et al., 205 
2006; Zdanov et al., 1995; Zdanov et al., 1996) and as a binary complex bound to its soluble 206 
receptor (Josephson et al., 2001). These studies demonstrated that cIL-10, like all members of the 207 
IL-10 family of class II cytokines, possesses a characteristic α-helical fold consisting of six 208 
helices (A to F) and connecting loops (Fig. 4a). It is secreted as a domain-swapped homodimer in 209 
which two adjacent non-covalently bounded peptides exchange helices E and F to form a twofold 210 
symmetric, V-shaped reciprocal dimer (Zdanov et al., 1995). The crystal structures of EBV and 211 
HCMV cmvIL-10 have been determined (Jones et al., 2002; Yoon et al., 2005; Zdanov et al., 212 
1997) (Fig. 4c and d), and were proved to be similar to that of human IL-10 with exception that 213 
HCMV cmvIL-10 lacks helix B (Jones et al., 2002). Using the receptor-bound structure of 214 
human IL-10 as template (Josephson et al., 2001), the three-dimensional protein structures of the 215 
CyHV-3 and AngHV-1 vIL-10s and the cIL-10s of their respective host were predicted (van 216 
Beurden et al., 2011) (Fig. 4e and f). These in silico analyses suggested that the vIL-10s encoded 217 
by these two alloherpesviruses share the conserved structure described for cIL-10. 218 
 219 
6. Transcriptomic and proteomic expression of vIL-10 genes 220 
Expression of vIL-10 genes has been studied at the RNA and protein levels. Depending 221 
on the viral species, genes encoding vIL-10s have been shown to be transcribed during in vitro 222 
replication at early times for rhesus cytomegalovirus (RhCMV) (Lockridge et al., 2000), HCMV 223 
LAcmvIL-10 (Jenkins et al., 2008a) and CyHV-3 (Ilouze et al., 2012), at early-late times for 224 
CyHV-3 (Ouyang et al., 2013), or at late times for EBV (Hudson et al., 1985; Miyazaki et al., 225 
1993; Touitou et al., 1996), HCMV cmvIL-10 (Chang et al., 2004) and AngHV-1 (van Beurden 226 
et al., 2013). 227 
The HCMV UL111A gene encodes a vIL-10 and has been shown to generate different 228 
transcripts during lytic and latent infections as a consequence of differential splicing (Kotenko et 229 
al., 2000; Jenkins et al., 2004). HCMV cmvIL-10 is expressed during the productive phase of 230 
infection (Spencer et al., 2002; Chang et al., 2004), whereas LAcmvIL-10 has been reported to 231 
be expressed during both latent (Jenkins et al., 2004) and productive infections (Jenkins et al., 232 
2008a). Both transcripts share the same initiation codon. However, as a result of the lack of 233 
splicing of the second intron, LAcmvIL-10 retains only the first two exons present in the lytic 234 
transcript (cmvIL-10), resulting in an in-frame stop codon 12 codons after the second exon. As a 235 
consequence, LAcmvIL-10 encodes a truncated protein of 139 residues that shares its first 127 236 
residues with the longer protein encoded by the cmvIL-10 transcript (Jenkins et al., 2004). Also, 237 
Lin et al. (2008) described five cmvIL-10 isoforms resulting from alternative splicing during in 238 
vitro replication of HCMV (Lin et al., 2008). 239 
EBV BCRF1 was classified as a late gene (Hudson et al., 1985), although it is expressed 240 
in B cells relatively early after infection (Jochum et al., 2012; Miyazaki et al., 1993). There is no 241 
evidence for BCRF1 transcription and protein secretion during in vitro latency. However, in in 242 
vivo studies, Xu et al. (2001) detected expression of BCRF1 in latently infected patients with 243 
NK/T-cell lymphoma (Xu et al., 2001). 244 
Expression of CyHV-3 ORF134, which encodes a vIL-10, has been detected in vivo 245 
during acute primary infection and subsequent reactivation phases. Expression during persistent 246 
infection at restrictive temperature was low or below the detection level (Sunarto et al., 2012). 247 
Secretion of vIL-10 in the extracellular compartment has been demonstrated for several 248 
viruses in cell culture: RhCMV (Lockridge et al., 2000), HCMV (cmvIL-10) (Chang et al., 249 
2004), EBV (Touitou et al., 1996) and CyHV-3 (Ouyang et al., 2013). In vivo secretion has been 250 
demonstrated for RhCMV (Lockridge et al., 2000). 251 
The effect of vIL-10 on virus growth in vitro has been studied using recombinant strains 252 
containing knock-out or nonsense mutations. For all viruses tested, vIL-10 genes were shown to 253 
be non-essential for growth of HCMV (Dunn et al., 2003), RhCMV (Chang & Barry, 2010), 254 
EBV (Jochum et al., 2012), CyHV-3 (Ouyang et al., 2013) and ORFV (Fleming et al., 2007). 255 
 256 
7. Ligand-receptor complexes formed by IL-10 orthologues 257 
Cellular IL-10 acts through a specific cell surface receptor (IL-10R) complex, which is 258 
composed of two different class II cytokine receptor family (CRF2) subunits, IL-10R1 and 259 
IL-10R2 (Moore et al., 2001; Zdanov, 2004). IL-10R1 is the high-affinity receptor subunit of 260 
cIL-10 and is expressed mainly on immune cells (Liu et al., 1994). Cellular IL-10 first binds to 261 
IL-10R1, which leads to changes of its conformation and subsequent association with the low-262 
affinity receptor subunit IL-10R2 (Yoon et al., 2006). In contrast to IL-10R1, IL-10R2 has a 263 
broader expression pattern, being expressed on most immune and non-immune cells. However, 264 
IL-10R2 is unable to bind cIL-10 in the absence of IL-10R1 (Kotenko et al., 1997; Wolk et al., 265 
2004). Binding of cIL-10 to the IL-10R complex activates a signalling pathway, which mainly 266 
acts through receptor-associated Janus kinase 1 (Jak1, associated with IL-10R1), Tyrosine kinase 267 
2 (Tyk2, associated with IL-10R2) and Signal transduction and transcription (STAT) factors, 268 
leading to initiation of transcription of the appropriate genes (Sabat et al., 2010). 269 
HCMV cmvIL-10 and EBV vIL-10 have been shown to bind to and signal through 270 
human IL-10R1 (Jones et al., 2002; Yoon et al., 2005). The regions of the surfaces of the human 271 
IL-10 and vIL-10 variants that make contact with the receptor are essentially the same. The 272 
binding affinity of HCMV cmvIL-10 (which exhibits only 27% sequence similarity with human 273 
IL-10) to soluble IL10R1 (sIL10 R1) is essentially similar to that of human IL-10 (Jones et al., 274 
2002). Furthermore, HCMV cmvIL-10 induces phosphorylation of the transcription factor 275 
STAT3 in monocytes, indicating its ability to bind and signal through human IL-10R in a manner 276 
comparable to that of human IL-10 (Jenkins et al., 2008b). The same authors blocked the ability 277 
of cmvIL-10 to down-regulate the MHC class II expression on monocytes by using neutralizing 278 
antibodies raised against human IL-10R (Jenkins et al., 2008b). None of the five cmvIL-10 279 
isoforms resulting from alternative splicing during in vitro replication of HCMV induced 280 
phosphorylation of STAT 3 despite being able to bind to human IL-10R (Lin et al., 2008). In 281 
contrast to cmvIL-10, LAcmvIL-10 does not induce STAT3 phosphorylation and retains the 282 
ability to reduce MHC class II expression on monocytes in the presence of neutralizing 283 
antibodies raised against human IL-10R (Jenkins et al., 2008b). These results suggest that 284 
LAcmvIL-10 does not bind to human IL-10R or acts through another receptor or binds to human 285 
IL-10R but in a different way as compared to cmvIL-10 and human IL-10. These variations most 286 
probably resulted from the fact that LAcmvIL-10 is a truncated protein that lacks C-terminal 287 
helices E and F. As a consequence LAcmvIL-10 lacks many of immunosuppressive functions 288 
(see below) that are known for cmvIL-10 (Jenkins et al., 2008b). 289 
The most prominent structural difference between human IL-10 and HCMV cmvIL-10 290 
bound to sIL-10R1 is the ~40º interdomain angle, which forces a reorganization of the IL-10R1 291 
subunits in the putative cell surface complex (Jones et al., 2002). The binding affinity of EBV 292 
vIL-10 (which has 92% sequence identity to human IL-10) to cell surface IL-10R1 is 293 
approximately a thousand-fold lower than that of human IL-10 (Liu et al., 1997). This difference 294 
in receptor binding affinity is thought to be caused by subtle changes in the conformation and 295 
dynamics of two loop structures and the interdomain angle (Yoon et al., 2005), as well as by 296 
single amino acid substitutions (Ding et al., 2000). 297 
Because the crystal structures of human IL-10 and EBV vIL-10 are very similar, the 298 
observed functional differences (described below) have been attributed to differences in binding 299 
affinity (Ding et al., 2001; Liu et al., 1997). Recently, the biological effect induced by CyHV-3 300 
vIL-10 in zebrafish embryos was shown to be abrogated by down-regulation of IL-10R1 301 
expression using a specific morpholino, suggesting that CyHV-3 vIL-10 functions also through 302 
IL-10R1 (Sunarto et al., 2012). 303 
 304 
8. Biological activities of IL-10 orthologues 305 
 306 
8.1 Biological activities of cIL-10 307 
Cellular IL-10 was first described as cytokine synthesis inhibitory factor (CSIF), an 308 
immune mediator that is produced by Th2 cell clones and has inhibitory effects on the synthesis 309 
of IL-2 and IFN-γ by Th1 cell clones (Fiorentino et al., 1989). Today, it is known that many 310 
different myeloid and lymphoid cells have the ability to produce IL-10 (Couper et al., 2008; 311 
Mosser & Zhang, 2008; Sabat et al., 2010), and that infection by a single pathogen species 312 
induces secretion of cIL-10 by more than one cell population, depending on the type of 313 
pathogen, the infected tissue and the time point in the immune response (Sabat et al., 2010). 314 
Cellular IL-10 is a type II pleiotropic cytokine with both immunostimulatory and 315 
immunosuppressive properties (Moore et al., 2001). However, the key features of this cytokine 316 
relate to its capacity to exert potent immunosuppressive functions on several immune cell types 317 
(Moore et al., 1993). It shows a clear, direct immunosuppressive effect on activated 318 
monocytes/macrophages, both by inhibition of the release of pro-inflammatory mediators 319 
(TNF-α, IL-1β, IL-6, IL-8, granulocyte colony-stimulating factor [G-CSF] and 320 
granulocyte-macrophage colony-stimulating factor [GM-CSF]) (de Waal Malefyt et al., 1991a; 321 
Fiorentino et al., 1991) and by enhancing the release of anti-inflammatory mediators (such as 322 
IL-1 receptor antagonist and soluble TNF-α receptor) (Hart et al., 1996; Jenkins et al., 1994). 323 
Additionally, cIL-10 inhibits antigen presentation by down-regulation of the expression of MHC 324 
class I, MHC class II and B7-1/B7-2 co-stimulatory molecules (de Waal Malefyt et al., 1991b; 325 
Matsuda et al., 1994; Willems et al., 1994). It also affects dendritic cells (DCs) by preventing 326 
their differentiation from monocyte precursors, and their maturation (Allavena et al., 1998; 327 
Demangel et al., 2002). Furthermore, cIL-10 hampers the development of Th1 immunity, both 328 
indirectly by inhibiting IL-12 synthesis by antigen presenting cells (APCs) and directly by 329 
inhibiting IL-2 and IFN-γ production by Th1 cells (D'Andrea et al., 1993; Fiorentino et al., 330 
1991). Moreover, cIL-10 acts directly on Th2 cells and inhibits IL-4 and IL-5 synthesis (Del 331 
Prete et al., 1993). Cellular IL-10 has also immunosuppressive effect on neutrophilic and 332 
eosinophilic granulocytes by preventing the synthesis of lipopolysaccaride (LPS)-induced 333 
pro-inflammatory mediators (Cassatella et al., 1993; Takanaski et al., 1994). Thus, cIL-10 plays 334 
a key role in the inhibition of the pro-inflammatory responses. It is thought that the role of this 335 
inhibition is to protect tissues from the lesions that could result from exaggerated inflammation 336 
(Banchereau et al., 2012). 337 
Notably, apart from its immunosuppressive role, cIL-10 also shows a stimulatory effect 338 
on several types of immune cell. It may prevent apoptosis of B cells, enhancing their activation 339 
and contributes to immunoglobulin class switching (Go et al., 1990; Rousset et al., 1992). 340 
Cellular IL-10 alone or in combination with other cytokines may also have a stimulatory effect 341 
on proliferation of, and cytokine production by, certain subsets of cytotoxic T cells (Rowbottom 342 
et al., 1999; Santin et al., 2000), mast cells (Thompson-Snipes et al., 1991) and NK cells (Cai et 343 
al., 1999; Carson et al., 1995). 344 
 345 
8.2. Biological activities of vIL-10s 346 
The biological activities of vIL-10s have been studied mainly in vitro using recombinant 347 
proteins generated from bacterial or mammalian cell expression systems, supernatants from viral 348 
infected cultures, or, to a lesser extent, recombinant vIL-10 knock-out viruses. Only a restricted 349 
number of studies have addressed the roles of vIL-10s in vivo by comparing wild type and 350 
vIL-10 knock-out viruses. These in vitro and in vivo studies are summarized below. In vitro 351 
studies are presented according to the immune process affected by vIL-10s, while in vivo studies 352 
are organized per virus species studied. 353 
 354 
8.2.1 Biological activities of vIL-10s determined in vitro 355 
8.2.1.1 Inhibition of cytokine synthesis and leukocyte proliferation. 356 
The hallmark activity of cIL-10 is the inhibition of cytokine production following 357 
pro-inflammatory signals. In vitro studies suggest that this activity is conserved among most 358 
viral orthologues. The studies supporting this conclusion are summarized below. 359 
HCMV cmvIL-10 inhibits gene expression and secretion of pro-inflammatory cytokines 360 
by LPS-stimulated peripheral blood mononuclear cells (PBMCs), monocytes, monocyte-derived 361 
dendritic cells (MDDCs) and plasmacytoid dendritic cells (PDCs) (Avdic et al., 2013; Chang et 362 
al., 2009; Chang et al., 2004; Jenkins et al., 2008b; Nachtwey & Spencer, 2008; Raftery et al., 363 
2004; Spencer, 2007; Spencer et al., 2002). Similarly, the orthologous RhCMV vIL-10 has been 364 
shown to inhibit production of pro-inflammatory cytokines by LPS-stimulated PBMCs and 365 
monocytes (Logsdon et al., 2011; Spencer et al., 2002). In addition, both HCMV cmvIL-10 and 366 
RhCMV vIL-10 reduced IFN-γ production by PHA-stimulated human PBMCs, as well as human 367 
and rhesus PBMC proliferation (Spencer et al., 2002). HCMV cmvIL-10 secreted by 368 
HCMV-infected cells can directly suppress the synthesis of type I IFNs by plasmacytoid 369 
dendritic cells (PDCs) (Chang et al., 2009), demonstrating that HCMV cmvIL-10 can act in 370 
trans, since PDCs are highly resistant to infection by HCMV (Slobedman et al., 2009). HCMV 371 
cmvIL-10 has a marked impact on microglial cells, which play a role in host defense against 372 
HCMV brain infection. Pretreatment of microglial cells with recombinant HCMV cmvIL-10 373 
prior to stimulation with HCMV significantly decreased the protein level of CXC chemokine 374 
ligand 10 (CXCL10), which is known to be involved in the recruitment of activated T 375 
lymphocytes in infected tissues (Cheeran et al., 2003). Very recent studies demonstrated that 376 
cmvIL-10 influence monocyte polarization by induction of development of M2 alternatively 377 
activated monocytes type c (M2c). The M2c polarization of monocytes by cmvIL-10 resulted in 378 
up-regulation of the anti-inflammatory enzyme heme oxygenase 1 (HO-1), and this was shown to 379 
play an important role in viral IL-10-mediated suppression of pro-inflammatory cytokines by 380 
M2c monocytes (Avdic et al., 2013). Moreover, M2c monocyte polarization by cmvIL-10 381 
reduces the ability to stimulate CD4+ T cell activation and proliferation (Avdic et al., 2013). 382 
In contrast to cmvIL-10, LAcmvIL-10 showed no inhibitory effect on IL-1α, IL-1β, IL-6 383 
or TNF-α expression by LPS-stimulated MDDCs (Jenkins et al., 2008b). However, in another 384 
study, it has been shown to inhibit TNF-α production by THP-1 myeloid cells stimulated with 385 
LPS (Spencer et al., 2008). Finally, Avdic et al. (2011) demonstrated significantly higher levels 386 
of transcription and secretion of cytokines associated with DC formation, as well as an increase 387 
in the proportion of myeloid DCs in CD34+ primary myeloid progenitor cells latently infected 388 
with HCMV deleted for the UL111A gene region, compared to parental virus or mock infection 389 
(Avdic et al., 2011). 390 
EBV vIL-10 inhibits pro-inflammatory cytokine production by activated cells of various 391 
types (de Waal Malefyt et al., 1991a; Hsu et al., 1990; Jochum et al., 2012; Salek-Ardakani et 392 
al., 2002b; Vieira et al., 1991). In addition, it reduces both the amount of IFN-γ mRNA (Niiro et 393 
al., 1992) and IFN-γ secretion (Salek-Ardakani et al., 2002b) in activated human PBMCs. 394 
Jochum et al., 2012 demonstrated that human PBMCs infected with EBV deleted for BCRF1 395 
produced significantly higher levels of the pro-inflammatory cytokines IFN-γ, IL-2, IL-6 and 396 
TNF-β, whereas levels of IL-1, IL-5, IL-8 and TNF-α were similar to those observed with the 397 
parental wild type strain. Interestingly, these authors also observed an increased production of 398 
human IL-10 by PBMCs infected with the BCRF1deleted strain. This observation suggests that 399 
vIL-10 could regulate human IL-10 expression. However, the observed effect could also have 400 
been an indirect consequence of the higher level of pro-inflammatory cytokines resulting from 401 
infection by the EBV vIL-10-deleted recombinant (Jochum et al., 2012). Finally, Brodeur and 402 
Spencer (2010) demonstrated that anti-human IL-10 antibodies bind to and neutralize the 403 
immunosuppressive activity of EBV vIL-10 but not HCMV cmvIL-10. This observation is 404 
consistent with the higher homology existing between EBV vIL-10 and human IL-10 (92.3% of 405 
identity) compared to HCMV cmvIL-10/ human IL-10 (27.3% of identity). 406 
The inhibition of cytokine activities were also demonstrated for two viruses infecting 407 
sheep (OvHV2 and ORFV) using different in vitro systems. OvHV2 vIL-10 inhibited IL-8 408 
production by LPS-stimulated ovine macrophages (Jayawardane et al., 2008) whereas ORFV 409 
vIL-10 inhibited TNF-α and IL-8 production from LPS-stimulated ovine macrophages and 410 
ionophore/PMA stimulated keratinocytes, as well as IFN-γ and GM-CSF production by 411 
Con-A-stimulated PBMCs (Haig et al., 2002a, b). However, ORFV vIL-10 knock-out virus 412 
showed no effect on infected keratinocyte IL-8 and TNF-α production (Haig et al., 2002b). 413 
ORFV vIL-10 has also been shown to inhibit expression and secretion of TNF-α in 414 
LPS-activated mouse peritoneal macrophages (Imlach et al., 2002), to inhibit TNF-α and IL-1β 415 
in the human monocyte cell line THP-1 activated by LPS (Imlach et al., 2002; Wise et al., 2007), 416 
and to inhibit production of IL-8, IL-1β and TNF-α in LPS-stimulated ovine alveolar 417 
macrophages (Fleming et al., 2000). Furthermore, inhibition of IFN-γ production in PBMCs by 418 
ORFV vIL-10 was demonstrated (Fleming et al., 2000). Compared to human IL-10, ORFV 419 
vIL-10 possesses reduced ability to impair THP-1 monocyte proliferation in the presence of LPS 420 
(Wise et al., 2007). However, it would be interesting to compare the biological activities of 421 
ORFV vIL-10 to those of ovine IL-10. 422 
 423 
8.2.1.2 Deregulation of MHC and co-stimulatory molecule expression 424 
Studies of the vIL-10s encoded by HCMV and EBV have demonstrated their ability to 425 
deregulate MHC and co-stimulatory molecule expression. HCMV cmvIL-10 and RhCMV 426 
vIL-10 reduced cell surface expression of classical MHC class I and class II molecules 427 
(Jaworowski et al., 2009; Jenkins et al., 2008b; Raftery et al., 2004; Spencer et al., 2002), but 428 
also increased expression of the non-classical MHC molecules HLA-DM and HLA-G on 429 
LPS-stimulated human MDDCs and monocytes, respectively (Raftery et al., 2004; Spencer et 430 
al., 2002). These observations suggest that HCMV cmvIL-10 could prevent antigen presentation 431 
to T cells through MHC class I molecule down-regulation but could simultaneously protect 432 
MHC class I-negative cells from NK cell-mediated lysis through up-regulation of HLA-G 433 
(Rouas-Freiss et al., 1997). Although independent studies demonstrated the inhibitory effect of 434 
HCMV cmvIL-10 on MHC class I expression in different LPS-stimulated cell types, Pepperl-435 
Klindworth et al. (2006) suggested that HCMV cmvIL-10 secreted during the productive phase 436 
of HCMV infection has no direct impact on MHC class I-restricted antigen presentation on non-437 
infected bystander cells in the context of viral infection (Pepperl-Klindworth et al., 2006). 438 
HCMV cmvIL-10 has also been shown to inhibit LPS-induced enhancement of co-stimulatory 439 
molecules (CD40, CD80, CD86, B7-H1 and B7-DC) on the surface of MDDCs (Jenkins et al., 440 
2008b; Raftery et al., 2004). LAcmvIL-10 reduces the expression of MHC class II molecules, 441 
but, in contrast to cmvIL-10, does not down-regulate expression of MHC class I molecules and 442 
co-stimulatory molecules (CD40, CD80, and CD86) on LPS-stimulated MDDCs (Jenkins et al., 443 
2008b). The reduction of cell surface MHC class II molecule expression by LAcmvIL-10 was 444 
comparable to the effect of cmvIL-10 both on immature myeloid progenitor cells and human 445 
monocytes (Jaworowski et al., 2009; Jenkins et al., 2008b). Jenkins et al. (2008b) suggested a 446 
possible mechanism for the reduction of MHC class II cell surface expression at the level of the 447 
transcriptional activity of CIITA, a gene that encodes a protein regulating the transcription of 448 
genes involved in the MHC class II biosynthesis pathway. The authors demonstrated that cmvIL-449 
10, as well as LAcmvIL-10, significantly inhibited transcription of CIITA, and that this resulted 450 
in down-regulation of expression of HLA-DR α, β and invariant chain. In addition, both 451 
cmvIL-10 and LAcmvIL-10 may inhibit MHC class II surface expression acting at the 452 
post-translational level by blocking transport of MHC class II molecules to the cell surface 453 
(Jenkins et al., 2008b). In addition to the above-mentioned functional studies utilizing 454 
recombinant LAcmvIL-10, Cheung et al. (2009) demonstrated that CD34+ myeloid progenitor 455 
cells latently infected by an HCMV strain deleted for the UL111A gene expressed a higher level 456 
of surface MHC class II molecules compared to cells infected with the parental strain. Cells 457 
infected with the knock-out strain became recognizable by allogeneic and autologous CD4+ T 458 
cells (Cheung et al., 2009). 459 
EBV vIL-10 was shown to reduce both constitutive and IFN-γ- or IL-4-induced MHC 460 
class II cell surface expression on monocytes and macrophages (de Waal Malefyt et al., 1991b; 461 
Salek-Ardakani et al., 2002a, b). This resulted in a decrease of antigen presentation by 462 
monocytes, and, as a consequence, a reduction of T cell proliferation (de Waal Malefyt et al., 463 
1991b). EBV vIL-10 also inhibited the expression of adhesion molecule ICAM-1 and 464 
co-stimulatory molecules (CD80 and CD86) on monocytes and macrophages when added 465 
simultaneously with IFN-γ (Salek-Ardakani et al., 2002a). Interestingly, EBV vIL-10 inhibited 466 
IFN-γ-induced MHC class I expression on monocytes and macrophages only when it was added 467 
2 h prior to the addition of IFN-γ, suggesting that it affects an early step in the IFN-γ signalling 468 
pathway (Salek-Ardakani et al., 2002a). 469 
 470 
8.2.1.3. Inhibition of DC 471 
Dendritic cells play key roles in immune responses. Viral IL-10s have been shown to 472 
affect their maturation, functionality and survival. HCMV cmvIL-10 inhibited LPS-induced pro-473 
inflammatory cytokine production by immature DCs (Chang et al., 2004; Raftery et al., 2008), 474 
but was also shown to have pronounced long-term effects on mature DCs. Although it enhanced 475 
the migration of mature DCs towards peripheral lymph nodes, it also reduced their production of 476 
cytokine (Chang et al., 2004). In addition, the inability of mature DCs to secrete IL-12 was 477 
maintained, even when they were restimulated by the activated T-cell signal CD40 ligand in the 478 
absence of cmvIL-10. Finally, cmvIL-10 induced endogenous cIL-10 expression in DCs, further 479 
increasing its modulatory effects (Chang et al., 2004). 480 
Raftery et al. (2004) demonstrated that HCMV cmvIL-10, in contrast to EBV vIL-10, had 481 
additional effects on DCs that could affect negatively their roles in immunity. Firstly, it inhibited 482 
cell-surface expression of molecules involved in antigen presentation, co-stimulation and 483 
adhesion. Secondly, it increased apoptosis of LPS-stimulated immature DCs by blocking 484 
expression of the anti-apoptotic, long form cellular FLIP protein. Thirdly, it induced a strong 485 
activation of STAT3 (a key mediator in cIL-10 transduction signal) in immature DCs. Fourthly, 486 
it up-regulated expression of DC-SIGN and IDO on LPS-stimulated immature DCs (Raftery et 487 
al., 2004). DC-SIGN has been shown to play a role in DC infection with primary HCMV isolates 488 
(Halary et al., 2002), whereas synthesis of IDO by human DCs caused suppression of T cell 489 
responses (Hwu et al., 2000). In contrast to HCMV cmvIL-10, LAcmvIL-10 showed no 490 
inhibitory effect in LPS-stimulated immature DCs on the expression of pro-inflammatory 491 
cytokines, co-stimulatory molecules and the maturation marker CD83 (Jenkins et al., 2008b). 492 
However, using a recombinant virus deleted for the UL111A gene region, Avdic et al. (2011) 493 
demonstrated that HCMV vIL-10 expressed during latency inhibits differentiation of latently 494 
infected myeloid progenitor cells toward a DC phenotype, suggesting that LAcmvIL-10 may 495 
inhibit infected myeloid progenitors to differentiate into DCs, thereby limiting the presentation 496 
of latency-associated viral peptides by DCs (Avdic et al., 2011). 497 
Immature DCs exposed simultaneously to LPS and ORFV vIL-10 showed enhanced 498 
ovalbumin–FITC uptake and reduced IL-12 expression, indicating inhibition of maturation of 499 
DCs. Furthermore, ORFV vIL-10 inhibited the up-regulation of DC cell-surface markers of 500 
activation and maturation such as MHC class II, CD80, CD83 and CD86, and inhibited the 501 
capacity of DCs to activate CD4+ T cells (Chan et al., 2006). Similarly, ORFV vIL-10 inhibited 502 
maturation and expression of MHC class II, CD80 and CD86 in stimulated murine bone marrow-503 
derived dendritic cells (BMDCs), and reduced their ability to present antigens (Lateef et al., 504 
2003). 505 
8.2.1.4. Other immunosuppressive properties 506 
 In addition to the main immunosuppressive properties described above, some studies 507 
suggest potential additional immunosuppressive effects for some vIL-10s. HCMV cmvIL-10 508 
decreased matrix metalloproteinase activity and deregulated cell-to-cell or cell-matrix 509 
interactions of infected cytotrophoblasts and endothelial cells (Yamamoto-Tabata et al., 2004). 510 
EBV vIL-10 has been shown to impair some of the defense mechanisms of activated monocytes 511 
and macrophages. It inhibited production of the superoxide anion by PBMCs and monocytes 512 
(Niiro et al., 1992) and PGE2 expression by LPS-stimulated monocytes (Niiro et al., 1994). 513 
Furthermore, EBV vIL-10 inhibits NK/NKT cell-mediated lysis of infected B cells through a 514 
direct effect on these cytotoxic cells and also through an indirect inhibitory effect on the CD4+ T 515 
cells that contribute to the microenvironment required for NK/NKT cytotoxicity (Jochum et al., 516 
2012). 517 
 518 
8.2.1.5. Immunostimulatory properties 519 
 In addition to their immunosuppressive effects, some vIL-10s have retained at least some 520 
of the immunostimulatory properties of their cellular orthologues. HCMV cmvIL-10, but not 521 
LAcmvIL-10, showed a strong stimulatory effect on proliferation of the human B cell lymphoma 522 
Daudi cell line (Spencer et al., 2008) and induced the production of human IL-10 (which is a 523 
growth factor for B lymphocytes) (Jaworowski et al., 2009; Spencer et al., 2008). Jaworowski et 524 
al. (2009) studied the effect of cmvIL-10 and LAcmvIL-10 on monocytes. They demonstrated 525 
that cmvIL-10 but not LAcmvIL-10 increases the expression of Fcγ receptors CD32 and CD64, 526 
as well as Fcγ-receptor-mediated phagocytosis (Jaworowski et al., 2009). RhCMV vIL-10 has 527 
been shown to stimulate proliferation of TF-1/IL-10R1 cells, which are human erythroleukemic 528 
cells proliferating upon addition of human IL-10 to the media (Logsdon et al., 2011). 529 
EBV vIL-10 has also been shown to stimulate proliferation and differentiation of human 530 
B cells as well as immunoglobulin production (Defrance et al., 1992; Rousset et al., 1992; Stuart 531 
et al., 1995). However, EBV vIL-10 lacks several of the other immunostimulatory functions 532 
expressed by cIL-10, such as co-stimulation of mouse thymocyte proliferation, mast cell 533 
proliferation and up-regulation of MHC class II expression on B cells (Vieira et al., 1991). 534 
 The ability of the OvHV-2 and ORFV vIL-10s to stimulate cell proliferation to levels 535 
comparable to those obtained with ovine IL-10 has been demonstrated by independent studies. 536 
OvHV-2 vIL-10 induced proliferation of murine mast cell line D-36 in conjunction with IL-4 537 
(Jayawardane et al., 2008). ORFV vIL-10 has been shown to induce proliferation of murine 538 
thymocytes in the presence of IL-2 (Fleming et al., 1997), ovine mast cells stimulated with IL-3, 539 
murine mast cell line D-36 stimulated with IL-4 (Haig et al., 2002b) and murine MC/9 mast cells 540 
stimulated with IL-3 and IL-4 (Imlach et al., 2002). 541 
 542 
8.2.2 Biological activities of vIL-10s determined in vivo 543 
Numerous molecular and in vitro studies suggest that, following capture, there has been 544 
adaptive evolution of vIL-10 through positive selection to retain the properties most beneficial 545 
for the viral life cycle. However, very few studies have addressed the role of vIL-10 in vivo by 546 
comparison of a wild type strain and derived deleted and revertant strains. This approach, which 547 
is essential to drawing conclusions on biological relevance in vivo, has been followed for only 548 
three viruses: RhCMV, ORFV and CyHV-3. 549 
Chang and Barry (2010) demonstrated that RhCMV vIL-10 has various effects on both 550 
the innate and the adaptive immune responses against RhCMV in infected rhesus macaques. 551 
They performed comparative infections with a wild type strain and a derived recombinant strain 552 
deleted for UL111A. Skin biopsies from macaques infected with the deleted strain exhibited a 553 
higher level of cellularity at the site of infection but contained a lower frequency of CD68+ 554 
macrophages. The latter observation suggests that RhCMV vIL-10 could contribute to the 555 
recruitment of permissive cells on viral replication sites. RhCMV vIL-10 was also shown to 556 
reduce trafficking of myeloid DCs to draining lymph nodes and to decrease priming of naïve 557 
CD4+ T cells (Chang & Barry, 2010). Although RhCMV vIL-10 has no effect on IgM 558 
production, it inhibited B cell differentiation and antibody isotype switching, resulting in a 559 
permanent deficit of circulating anti-RhCMV IgG. In addition, RhCMV vIL-10 delayed antibody 560 
maturation and attenuated the magnitude of anti-viral antibody titre (Chang & Barry, 2010). 561 
Finally, it was also shown to reduce the frequency of RhCMV-specific effector T helper cells 562 
secreting IFNγ or IL-2, and T cell proliferation (Chang & Barry, 2010).  563 
The activity of vIL-10 encoded by ORFV in vivo has been analyzed in its natural host, the 564 
sheep. A preliminary study revealed that the frequency of IFNγ mRNA-expressing cells in skin 565 
lesions was higher in animals infected with the vIL-10 knock-out virus than in animals infected 566 
with the parental wild type virus (Fleming et al., 2000). Interestingly, after primary infection, 567 
smaller, less severe lesions were observed in animals infected with the vIL-10 knock-out virus 568 
than those observed in animals infected with the wild type parental or revertant strains (Fleming 569 
et al., 2007). 570 
Recently, the role of CyHV-3 vIL-10 was studied in vivo using an artificial zebrafish 571 
embryo model (Sunarto et al., 2012). It was shown that injection of CyHV-3 ORF134 mRNA 572 
into zebrafish embryos increased the number of lysozyme-positive cells to a degree similar to 573 
that of zebrafish IL-10 mRNA (Sunarto et al., 2012). However, Ouyang et al. (Ouyang et al., 574 
2013) demonstrated that CyHV-3 vIL-10 does not significantly affect its virulence in common 575 
carp or the host innate immune response. Thus, infection of carp with ORF134-deleted, 576 
ORF134-revertant or wild type strains induced comparable levels of CyHV-3 disease (Ouyang et 577 
al., 2013). Moreover, quantification of viral load and real-time PCR investigating the expression 578 
of several carp inflammatory cytokines at various times post-infection did not revealed any 579 
significant differences between groups of fish infected with the three viral genotypes (Ouyang et 580 
al., 2013). Similarly, histological examination of the gills and the kidneys of infected fish 581 
revealed no significant differences between fish infected with the ORF134-deleted virus and 582 
those infected with the control parental or revertant strains (Ouyang et al., 2013). All together, 583 
the results demonstrated that CyHV-3 vIL-10 is essential for neither viral replication in vitro nor 584 
virulence in common carp. 585 
 586 
9. Viral IL-10s as a topic of applied research 587 
In addition to their importance in fundamental research, a large number of studies 588 
demonstrate a role for vIL-10s in applied research. A thorough description of this abundant 589 
literature is beyond the scope of this review. Here, we briefly describe the two main types of 590 
applied research developed on vIL-10s. These studies investigate the potential of vIL-10s as 591 
candidate antigens or target genes (production of attenuated recombinant vaccines) for the 592 
development of anti-viral vaccine or as an immunosuppressor to prevent immunopathologies. 593 
For vIL-10s that alter innate or adaptive immunity in vivo, vaccine-mediated 594 
neutralization of their function could contribute to inhibition of the establishment of a persistent 595 
infection in naïve subjects or even interrupt a pre-existing persistent infection. This theoretical 596 
possibility could apply to most vIL-10s that are quite divergent in sequence from the host IL-10. 597 
To address this concept using the RhCMV model (Yue & Barry, 2008), inactive RhCMV vIL-10 598 
mutants were designed as antigen candidates and shown to induce the production of neutralizing 599 
antibodies specific to vIL-10 (not cross-reacting with host IL-10) (de Lemos Rieper et al., 2011; 600 
Logsdon et al., 2011). The ability of such an antigen candidate to interfere with persistent 601 
RhCMV infection (establishment or maintenance) has not yet been tested. However, a recent 602 
study on the immunogenicity of vIL-10 in RhCMV-infected rhesus macaques demonstrated that 603 
the serum of persistently infected animals contains high levels of vIL-10-neutralizing antibodies 604 
(Eberhardt et al., 2012). This observation suggests that vIL-10-based vaccines may not be able to 605 
interrupt an established persistent infection. Interestingly, development of antibodies against 606 
RhCMV vIL-10 in uninfected rhesus macaques immunized with plasmid vectors encoding for 607 
engineered, nonfunctional RhCMV vIL-10 variants resulted in reduction of RhCMV replication 608 
at the inoculation site and RhCMV shedding in bodily fluids during subcutaneous RhCMV 609 
challenge (Eberhardt et al., 2013). Alternatively, for vIL-10s playing a significant role in 610 
virulence, deleted recombinant strains could be produced as attenuated vaccines as suggested for 611 
RhCMV (Chang & Barry, 2010). 612 
The data presented in the previous section collectively indicate that vIL-10s, compared to 613 
cIL-10, have a restricted bioactivity profile favouring immunosuppressive activities. Based on 614 
this profile, several independent groups have suggested exploiting vIL-10s as potential 615 
immunosuppressive agents. Studies performed in laboratory animal models support this concept. 616 
Researchers have demonstrated the potential of some vIL-10s to induce localized 617 
immunosuppression in order to favour long-term engraftment of transplanted tissues (EBV 618 
vIL-10) (Nast et al., 1997; Qin et al., 1996), reduce the host’s foreign body reaction against 619 
implanted biomaterials (HCMV cmvIL-10) (van Putten et al., 2009), or treat collagen-induced 620 
arthritis (EBV vIL-10) (Keravala et al., 2006; Kim et al., 2000; Lechman et al., 1999; Ma et al., 621 
1998; Whalen et al., 1999).  622 
 623 
10. Concluding remarks 624 
Most viruses have been co-evolving with their hosts for millions of years. During this 625 
process, viruses and hosts have been acting as strong sources of selection pressure on each other. 626 
Thus, viruses have been constantly selecting individuals among the host population that have the 627 
most efficient immune systems, while the continual improvement of the immune system has 628 
been selecting viruses that have evolved strategies to control the host immune response. 629 
Fundamental studies in immunology have demonstrated the key roles of cIL-10 in the immune 630 
system. The various independent acquisitions of IL-10 orthologues by viruses belonging to 631 
different viral genera, subfamilies and even families further support the importance of cIL-10 in 632 
the immune system. After their capture by the viral genome, cellular sequences evolve through 633 
positive selection to retain properties that are the most beneficial for the virus, and, sometimes, to 634 
acquire novel properties. The vIL-10s illustrate this concept. In comparison to their cellular 635 
orthologues, vIL-10s have evolved towards a more restricted bioactivity profile consisting 636 
mainly, but not exclusively, of immunosuppressive activities. Interestingly, studies on HCMV 637 
cmvIL-10 and LAcmvIL-10 demonstrate that evolution of a captured IL-10 gene in the viral 638 
genome has led to the expression of two different transcripts that have specific biological 639 
activities adapted to the replication and latent phases. 640 
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Figure legends 649 
 650 
Fig. 1. Schematic representation of the genomic intron/exon organization of human IL-10 (H. 651 
sapiens, Genbank ID: NP_000563) and vIL-10s encoded by the viruses listed in Table 1. Boxes 652 
and horizontal lines represent exons and introns, respectively. They are drawn to scale. The 5’- 653 
and 3’-UTRs of human IL-10 are not shown. The homology existing between each human IL-10 654 
exons and virus IL-10s were investigated at the level of amino acid sequences using the 655 
accession numbers listed in Table 1 and the FASTA Sequence Comparison program 656 
(http://fasta.bioch.virginia.edu/fasta_www2/index.cgi) using default settings. Regions of vIL-10 657 
DNA sequences encoding amino acid sequences homologous to human IL-10 protein domain 658 
encoded by each exon are drawn to scale using the following colour code: exon 1: red, exon 2: 659 
yellow, exon 3: blue, exon 4: green, exon 5: orange. Regions of vIL-10s for which no homology 660 
could be detected are presented in grey. HCMV cmvIL-10 and LAcmvIL-10 represent transcripts 661 
of the HCMV UL111A gene expressed during lytic and latent infections, respectively. The 662 
former retains the structure of the gene consisting of three exons and two introns, and the latter 663 
retains only the first intron, resulting in an in-frame stop codon 12 codons after the second exon. 664 
 665 
Fig. 2. Maximum likelihood phylogenetic tree for cIL-10s, vIL-10s (listed in Table 1), the 134R 666 
protein encoded by Yaba-like disease virus, and selected members of the IL-20 family of 667 
cytokines. Sequences and methods used are described in supplementary file S1. The tree was 668 
build using MEGA (JTT+Γ substitution model) and 100 bootstrap replicates. Numbers of nodes 669 
indicate bootstrap confidence, where >70%. Cellular IL-10 and vIL-10s are collapsed into a 670 
single branch. Scale: substitutions per site. 671 
 672 
Fig. 3. Bayesian consensus tree built using BEAST for cIL-10s and vIL-10s. Sequences and 673 
methods used are described in supplementary file S1. Figures at nodes are posterior probabilities 674 
(where >70%) of common ancestry. Branch lengths are arbitrary. Four positionally orthologous 675 
sets of vIL-10 are framed. Independent gene acquisition events are marked by letters (A to I). 676 
 677 
Fig. 4. Structure of cIL-10s and selected vIL-10s. a) Crystal structure of human IL-10 from the 678 
IL-10/IL-10R1 complex (PDB ID: 1j7v (Josephson et al., 2001)). IL-10 protomers are depicted 679 
with helices rendered as cylinders. Helices are labelled. b) Ribbon diagram of the 1:2 IL-10/sIL-680 
10R1 complex viewed perpendicular to the twofold axis of IL-10 (reproduced with permission 681 
from Josephson et al., 2001). c) to f) Superposition of host and viral IL-10s modeled using 682 
human IL-10 as template (PDB ID: 1j7v). c) Human IL-10 (green, PDB ID: 1j7v (Josephson et 683 
al., 2001)) and EBV vIL-10 (blue, PDB ID: 1Y6M (Yoon et al., 2005)). d) Human IL-10 (green) 684 
and HCMV cmvIL-10 (brown, PDB ID: 1LQS (Jones et al., 2002)). e) European eel IL-10 (red) 685 
and AngHV1 vIL-10 (orange) (van Beurden et al., 2011). f) Common carp IL-10 (green) and 686 
CyHV-3 IL-10 (yellow) (van Beurden et al., 2011). The interdomain angles of each IL-10 687 
orthologue published previously are shown at the top of each complex. 688 
689 
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 Human cytomegalovirus HCMV UL111A/ 
cmvIL-10 
AAR31656 3/2 176 (25) Human 27.3% (Kotenko et al., 2000; 













Green monkey cytomegalovirus GMCMV UL111A (S) AEV80459 4/3 185 (26) Green 
monkey 
28.2% (Davison et al., 2013) 
Rhesus cytomegalovirus RhCMV U111A AAF59907 4/3 189 (31) Macaque 25.0% (Lockridge et al., 
2000) 
Baboon cytomegalovirus BaCMV vIL-10 (S) 
 
AAF63436 4/3 191 (33) Baboon 28.6% (Lockridge et al., 
2000) 
Owl monkey cytomegalovirus OMCMV UL111A (S) AEV80800 4/3 182 (21) Owl 
monkey 
30.3% (Davison et al., 2013) 
Squirrel monkey cytomegalovirus SMCMV UL111A (S) AEV80955 4/3 178 (18) Squirrel 
monkey 




        
 
Epstein-Barr virus EBV BCRF1 CAD53385 1/0 170 (23) Human 92.3% (Arrand et al., 1981) 
Bonobo herpesvirus Bonobo-HV LOC100970108 (S) XP_003804206.1  1/0 169 (18) Bonobo 94.3%  
Rhesus lymphocryptovirus RhLCV BCRF1 (S) AAK95412 1/0 177 (29) Macaque 97.2% (Franken et al., 1996) 
Baboon lymphocryptovirus BaLCV vIL-10 (S) AAF23949 1/0 171 (24) Baboon 91.6%  
Macavirus          
 
Ovine herpesvirus 2 OvHV-2 Ov2.5 AAX58040 5/4 182 (26) Sheep 49.6% (Meier-Trummer et 
al., 2009) 
Percavirus          
 




        
 
Cyprinid herpesvirus 3 CyHV-3 ORF134 ABG42961 2/1 179 (17) Common 
Carp 
26.9% (Aoki et al., 2007) 
 
Anguillid herpesvirus 1 AngHV-1 ORF25 AFK25321 1/0 165 (19) European 
eel 





























        




(Delhon et al., 2004) 
 
Bovine papular stomatitis virus BPSV ORF127 (S) AAR98483 1/0 185 (23) Cattle 94.4% (Delhon et al., 2004) 
 
Pseudocowpox virus PCPV ORF127 (S) ADC53770 1/0 199 (23) Cattle 87.3% (Hautaniemi et al., 
2010) 
Capripoxvirus          
 
Lumpy skin disease virus LSDV LSDV005 (S) AAK84966  1/0 170 (23) Cattle 45.7% (Tulman et al., 2001) 
 
Sheeppox virus SPV SPPV_03 (S) NP_659579 1/0 168 (25) Sheep 47.9% (Tulman et al., 2002) 
 Goatpox virus GPV  GTPV_gp003 (S) YP_001293197 1/0 170 (27) Goat 49.6% (Tulman et al., 2002) 
Avipoxvirus          
 Canarypox virus CNPV CNPV018 (S) NP_955041 1/0 191 (20) Passeriform 
birds 
* (Tulman et al., 2004) 
Tables 1119 
 1120 
Table 1. Features of vIL-10s. 1121 
Exon number and protein length were determined based on the sequences available in the public 1122 
databases. Signal peptides were predicted by using SignalP 4.0 1123 
(http://www.cbs.dtu.dk/services/SignalP/). Mature proteins (excluding signal peptide sequences) 1124 
were compared using the FASTA sequence comparison program 1125 
(http://fasta.bioch.virginia.edu/fasta_www2/). Protein sequence accession numbers for the hosts 1126 
are as follows: Homo sapiens (human; NP_000563), Macaca mulatta (rhesus macaque; 1127 
NP_001038192), Papio anubis (baboon; XP_003893246), Pan paniscus (bonobo; 1128 
XP_003822966.1), Ovis aries (sheep; emb|CAG38358), Capra hircus (goat; ABI20513), Bos 1129 
taurus (cow; NP_776513), Equus caballus (horse; NP_001075959), Cyprinus carpio (common 1130 
carp; BAC76885), Anguilla anguilla (European eel; AEL99923). SP: signal peptide; * no IL-10 1131 
consensus sequence is available for passeriform birds, S: Viruses for which the only available 1132 
data is the vIL-10 sequence. 1133 
 1134 




